AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainua) to treat adult ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for ...

VMPL Jaipur Rajasthan [India] October 23 In the heart of Rajasthan lies a beacon of hope for those seeking advanced ...

UK MHRA grants marketing authorisation to AstraZeneca’s eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Friday, October 18, 2024, ...

AstraZeneca and Ionis' drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...

Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU.